<bill session="116" type="h" number="2069" updated="2022-11-01T19:02:21Z">
  <state datetime="2019-04-03">REFERRED</state>
  <status>
    <introduced datetime="2019-04-03"/>
  </status>
  <introduced datetime="2019-04-03"/>
  <titles>
    <title type="display">SPIKE Act</title>
    <title type="official" as="introduced">To amend title XI of the Social Security Act to provide for drug manufacturer price transparency.</title>
    <title type="short" as="introduced">SPIKE Act</title>
    <title type="short" as="introduced">Stopping the Pharmaceutical Industry from Keeping drugs Expensive Act</title>
  </titles>
  <sponsor bioguide_id="H001066"/>
  <cosponsors>
    <cosponsor bioguide_id="C001055" joined="2019-04-30"/>
    <cosponsor bioguide_id="C001124" joined="2019-04-08"/>
    <cosponsor bioguide_id="H001085" joined="2019-04-30"/>
    <cosponsor bioguide_id="N000147" joined="2019-05-20"/>
    <cosponsor bioguide_id="R000606" joined="2019-04-30"/>
    <cosponsor bioguide_id="R000585" joined="2019-04-03"/>
    <cosponsor bioguide_id="S001208" joined="2019-05-20"/>
    <cosponsor bioguide_id="S001209" joined="2019-05-02"/>
    <cosponsor bioguide_id="S001213" joined="2019-11-18"/>
    <cosponsor bioguide_id="W000826" joined="2019-04-08"/>
  </cosponsors>
  <actions>
    <action datetime="2019-04-03">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-04-03" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2019-04-03">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2019-04-03">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2019-04-04">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2019-05-21">
      <text>Subcommittee Hearings Held.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Hearings, Referral"/>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
    <committee code="HSWM02" name="House Ways and Means" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="2113" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Business records"/>
    <term name="Civil actions and liability"/>
    <term name="Corporate finance and management"/>
    <term name="Government information and archives"/>
    <term name="Health care costs and insurance"/>
    <term name="Inflation and prices"/>
    <term name="Manufacturing"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2020-05-28T15:11:01Z" status="Introduced in House">Stopping the Pharmaceutical Industry from Keeping drugs Expensive Act or the SPIKE Act

This bill requires the Centers for Medicare &amp; Medicaid Services (CMS) to determine at least annually whether certain covered drugs under Medicare were subject to a price increase that exceeded specified thresholds. Drug manufacturers must submit justifications for such price increases to the CMS, subject to civil penalties. The bill's requirements do not apply to low-cost drugs, as identified by the CMS.</summary>
</bill>
